The overarching goal of the New Mexico MU-NCORP is to improve the quality of cancer care throughout our catchment area (the State of New Mexico) and to eliminate the tremendous burden of cancer health disparities in the multiethnic populations that we serve by building innovative statewide outreach programs, founded in community-based participatory research methods and scientific collaborations between community health systems and providers with the primary academic affiliate site, resulting in an increased awareness, acceptance, access, and participation by all New Mexicans in NCI-sponsored cancer screening, post-treatment surveillance, prevention, and therapeutic clinical trials. The University of New Mexico Comprehensive Cancer (UNMCCC) serves as the primary affiliate with strong scientific programs in cancer population sciences, cancer control, health disparities, and clinical interventions, in partnership with nearly all New Mexico health systems and community cancer care sites that are consortium members of the New Mexico Cancer Care Alliance (NMCCA, secondary affiliate), a joint 501c3 statewide clinical trials research network that provides the major clinical trials infrastructure to support the goals of the NCI NCORP. This NM MU-NCORP organization continues to engage all stakeholders in our cancer health mission and builds upon a well-established 20 year partnership supported in part by prior NCI MB-CCOP and current NCORP grants. This consortium has a proven track record and success in enrolling New Mexico's highly diverse multiethnic, rural, and underserved cancer patients in NCTN trials and has launched several cancer care delivery (CCDR) trials that are of great interest to our community partners. The NM MU-NCORP will continue to be actively engaged in developing research strategies across the NCORP Research Bases and will serve as working partners throughout the NCORP Network. With the highest percentage of Hispanics and American Indians of any state, New Mexico's 2.1 million citizens are 39% non- Hispanic White, 47% Hispanic, 10% American Indian, 2.4% Black, and 1.6% Asian and other ethnic minorities. New Mexico ranks at the bottom (48th) in the U.S. in annual per capita income and a substantial number of New Mexicans, particularly its minority populations, are poor, rural, and underserved. With the nation's highest rate (30%) of childhood poverty, nearly 20% of all New Mexicans live in poverty and 10-13% of New Mexicans, depending on the county, still lack health insurance. Our research strategy is focused on academic/community team partnerships to address all aspects of cancer screening, prevention, cancer control, cancer care delivery, and therapeutic intervention in order to prioritize and optimize trial-based cancer care, while enhancing collaboration with the NCORP Research Bases in order to generate the next generation of trials to address the cancer disparities of the New Mexicans served by the MU-NCORP.

Public Health Relevance

The relevance of the New Mexico Minority-Underserved NCORP (MU-NCORP) lies in the deep rooted mission of our longstanding partnership of academic and community cancer providers and other community stakeholders managed through a unique statewide consortium infrastructure (UNM Comprehensive Cancer Center and the New Mexico Cancer Care Alliance) to deliver the highest quality in all aspects of cancer care (cancer screening, prevention control and cancer care delivery) to all New Mexicans with a strong focus on eradicating disparities in access, care delivery and outcomes. Our growth as an NCI Comprehensive Cancer Center with scientific programmatic focus on innovative approaches to cancer delivery and disparities research in our unique New Mexican populations in conjunction with our longstanding community partnerships through nearly 20 years of work as an MB-CCOP and now MU-NCOORP continues to support our progress in meaningful reduction in cancer burden and better understanding of barriers to care for our population. Continued team work with all academic, community oncology and tribal and other community stakeholders while serving as leaders within the NCI NCORP, CTEP and DCP with bidirectional research engagement will continue to strengthen our program and effectiveness in improving quality and length of life for New Mexicans and other minority populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189856-06
Application #
9774691
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Pak, Jennifer Soyoung
Project Start
2014-08-09
Project End
2025-07-31
Budget Start
2019-08-09
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of New Mexico Health Sciences Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Carlos, Ruth C; Sicks, JoRean D; Chang, George J et al. (2017) Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14:1530-1537
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Marur, Shanthi; Li, Shuli; Cmelak, Anthony J et al. (2017) E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490-497
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74

Showing the most recent 10 out of 13 publications